Please use this identifier to cite or link to this item: https://doi.org/10.1007/s00198-012-2224-2
DC FieldValue
dc.titleHealth risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study
dc.contributor.authorPrentice, R.L
dc.contributor.authorPettinger, M.B
dc.contributor.authorJackson, R.D
dc.contributor.authorWactawski-Wende, J
dc.contributor.authorLacroix, A.Z
dc.contributor.authorAnderson, G.L
dc.contributor.authorChlebowski, R.T
dc.contributor.authorManson, J.E
dc.contributor.authorVan Horn, L
dc.contributor.authorVitolins, M.Z
dc.contributor.authorDatta, M
dc.contributor.authorLeblanc, E.S
dc.contributor.authorCauley, J.A
dc.contributor.authorRossouw, J.E
dc.date.accessioned2020-10-27T04:48:32Z
dc.date.available2020-10-27T04:48:32Z
dc.date.issued2013
dc.identifier.citationPrentice, R.L, Pettinger, M.B, Jackson, R.D, Wactawski-Wende, J, Lacroix, A.Z, Anderson, G.L, Chlebowski, R.T, Manson, J.E, Van Horn, L, Vitolins, M.Z, Datta, M, Leblanc, E.S, Cauley, J.A, Rossouw, J.E (2013). Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporosis International 24 (2) : 567-580. ScholarBank@NUS Repository. https://doi.org/10.1007/s00198-012-2224-2
dc.identifier.issn0937-941X
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/180805
dc.description.abstractThe Women's Health Initiative (WHI) double-blind, placebo-controlled clinical trial randomly assigned 36,282 postmenopausal women in the U.S. to 1,000 mg elemental calcium carbonate plus 400 IU of vitamin D3 daily or placebo, with average intervention period of 7.0 years. The trial was designed to test whether calcium plus vitamin D supplementation in a population in which the use of these supplements was widespread would reduce hip fracture, and secondarily, total fracture and colorectal cancer. Introduction: This study further examines the health benefits and risks of calcium and vitamin D supplementation using WHI data, with emphasis on fractures, cardiovascular disease, cancer, and total mortality. Methods: WHI calcium and vitamin D randomized clinical trial (CT) data through the end of the intervention period were further analyzed with emphasis on treatment effects in relation to duration of supplementation, and these data were contrasted and combined with corresponding data from the WHI prospective observational study (OS). Results: Among women not taking personal calcium or vitamin D supplements at baseline, the hazard ratio [HR] for hip fracture occurrence in the CT following 5 or more years of calcium and vitamin D supplementation versus placebo was 0.62 (95 % confidence interval (CI), 0.38-1.00). In combined analyses of CT and OS data, the corresponding HR was 0.65 (95 % CI, 0.44-0.98). Supplementation effects were not apparent on the risks of myocardial infarction, coronary heart disease, total heart disease, stroke, overall cardiovascular disease, colorectal cancer, or total mortality, while evidence for a reduction in breast cancer risk and total invasive cancer risk among calcium plus vitamin D users was only suggestive. Conclusion: Though based primarily on a subset analysis, long-term use of calcium and vitamin D appears to confer a reduction that may be substantial in the risk of hip fracture among postmenopausal women. Other health benefits and risks of supplementation at doses considered, including an elevation in urinary tract stone formation, appear to be modest and approximately balanced. © 2012 The Author(s).
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectcalcium
dc.subjectplacebo
dc.subjectvitamin D
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectcancer risk
dc.subjectcardiovascular disease
dc.subjectcerebrovascular accident
dc.subjectcolorectal cancer
dc.subjectfemale
dc.subjecthealth hazard
dc.subjectheart infarction
dc.subjecthip fracture
dc.subjecthuman
dc.subjectischemic heart disease
dc.subjectmajor clinical study
dc.subjectmortality
dc.subjectobservational study
dc.subjectpriority journal
dc.subjectrisk benefit analysis
dc.subjectrisk reduction
dc.subjecttreatment duration
dc.subjectvitamin supplementation
dc.subjectAged
dc.subjectBone Density Conservation Agents
dc.subjectCalcium Carbonate
dc.subjectCardiovascular Diseases
dc.subjectCholecalciferol
dc.subjectDietary Supplements
dc.subjectDouble-Blind Method
dc.subjectDrug Administration Schedule
dc.subjectDrug Therapy, Combination
dc.subjectFemale
dc.subjectHip Fractures
dc.subjectHumans
dc.subjectMiddle Aged
dc.subjectNeoplasms
dc.subjectOsteoporosis, Postmenopausal
dc.subjectOsteoporotic Fractures
dc.subjectRisk Assessment
dc.subjectUnited States
dc.subjectUrinary Calculi
dc.typeArticle
dc.contributor.departmentOBSTETRICS & GYNAECOLOGY
dc.description.doi10.1007/s00198-012-2224-2
dc.description.sourcetitleOsteoporosis International
dc.description.volume24
dc.description.issue2
dc.description.page567-580
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1007_s00198-012-2224-2.pdf215.84 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons